Other

Institut Pasteur

Institute Pasteur

Hellenic Pasteur Institute

Institut Pasteur Hellenique

Penelope Mavromara

Urania Georgopoulou

Agoritsa Varaklioto

Niki Vassilaki

The present invention relates to a novel form of core+1 protein of Hepatitis C virus (HCV), designated shorter form core+1 protein. The shorter form core+1 protein of Hepatitis C virus is the product of translation of a coding sequence consisting of all or part of a nucleotide sequence extending from nucleotide 598 to nucleotide 920 within the core+1 ORF of HCV represented on FIG.B. The invention also provides methods for detecting infection by Hepatitis C virus in biological samples, methods of screening compounds which interact with viral propagation in HCV infected cells or screening of compounds impaction on the expression of shorter form core+1 protein and uses of these compounds for the preparation of compositions useful for their anti-viral activities.

HCV core+1 protein, methods for diagnosis of HCV infections, prophylaxis, and for screening of anti-HCV agents

DNA encoding core+1 polypeptides of hepatitis C virus (HCV), nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.

Nucleic acids and new polypeptides associated with and/or overlapping with hepatitis C virus core gene products

DNA encoding core&plus;1 polypeptides of hepatitis C virus (HCV), nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.

Growing community of inventors

Athens, Greece

Penelope Mavromara